Robert Glassman Sells 10,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Robert Glassman sold 10,000 shares of Pharvaris stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $29.82, for a total transaction of $298,200.00. Following the transaction, the director directly owned 10,500 shares in the company, valued at $313,110. The trade was a 48.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Pharvaris Stock Up 0.5%

Pharvaris stock traded up $0.14 during midday trading on Tuesday, hitting $28.95. 301,435 shares of the stock were exchanged, compared to its average volume of 226,184. The company has a fifty day simple moving average of $28.20 and a two-hundred day simple moving average of $26.63. Pharvaris N.V. has a 52 week low of $15.46 and a 52 week high of $33.33. The stock has a market capitalization of $1.89 billion, a PE ratio of -9.10 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.12. As a group, equities research analysts anticipate that Pharvaris N.V. will post -3.35 EPS for the current fiscal year.

Pharvaris News Roundup

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates for Pharvaris across multiple quarters and fiscal years, including higher forecasts for FY2026 through FY2030, and maintained a Buy rating with a $60 price target.
• Neutral Sentiment: Pharvaris recently reported a smaller-than-expected quarterly loss, with EPS of ($0.70) versus the consensus estimate of ($0.82), which may support sentiment but does not change the company’s near-term loss profile.
• Negative Sentiment: Insider selling by Director Robert Glassman and insider Wim Souverijns, both of whom sold 10,000 shares, may temper enthusiasm slightly because it can be viewed as reduced insider confidence. SEC filing for Robert Glassman sale SEC filing for Wim Souverijns sale

Analyst Upgrades and Downgrades

PHVS has been the subject of several recent analyst reports. Wedbush increased their price target on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Royal Bank Of Canada lowered their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Citigroup restated a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Wolfe Research initiated coverage on Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $49.18.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after buying an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares during the period. Legal & General Group Plc raised its stake in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after buying an additional 1,695 shares during the period. Amundi raised its stake in Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after buying an additional 27,416 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock valued at $860,000 after buying an additional 7,879 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.